Overview
HMB-45 (Human Melanoma Black-45) is a monoclonal antibody originally identified from melanoma tissue. It recognizes a melanosomal glycoprotein known as gp100 (also referred to as Pmel17), which is associated with premelanosomes. Human Melanoma Black-45 is considered a marker of melanocytic differentiation and is widely used in immunohistochemistry for the diagnosis of melanocytic lesions.
Human Melanoma Black-45 shows putative specificity for melanoma cells and stains activated or stimulated melanocytes. It reacts with junctional melanocytes in nevi, dermal nevus cells in certain pigmented lesions, cells in deep penetrating nevi, some melanocytes in dysplastic nevi, blue nevi, and Spitz nevi. It is regarded as a highly sensitive marker for melanoma cells, although it does not stain desmoplastic melanomas and may fail to stain some nevoid melanomas even when metastasis is present.
Role of HMB-45 in Melanocytic Lesions
Human Melanoma Black-45 immunostaining identifies an antigen associated with premelanosomal glycoproteins found in activated and neoplastic melanocytes. It specifically recognizes premelanosome protein gp100 and is localized within melanosomes, particularly in stage II and later stages of melanosome development.
Because of this localization, HMB-45 serves as a marker of active melanocytic differentiation. Its expression reflects melanosome formation rather than the mere presence of melanocytes, which explains its strong staining in many melanomas and variable staining in benign melanocytic lesions.
Symptoms
HMB-45 itself does not cause symptoms. It is a diagnostic marker used in tissue evaluation. Patients undergoing HMB-45 testing typically present with symptoms related to underlying skin or soft tissue lesions rather than symptoms directly linked to the marker.
Clinical presentation depends on the type and stage of the lesion, such as pigmented skin lesions, nodules, ulceration, or metastatic disease, prompting histopathological examination and immunohistochemical analysis.
Causes
HMB-45 positivity is caused by the presence of activated or neoplastic melanocytes expressing gp100 within premelanosomes. This expression is seen in malignant melanoma and certain benign melanocytic proliferations.
The variability in HMB-45 staining is related to the degree of melanocytic activation and differentiation. Tumors with reduced melanosome formation, such as desmoplastic melanoma, often show negative or weak staining despite being malignant.
Risk Factors
Risk factors influencing HMB-45 expression are closely linked to the biology of melanocytic tumors rather than patient-related factors. Malignant melanoma, metastatic melanoma, and undifferentiated carcinomas suspected of melanocytic origin are key indications for HMB-45 testing.
HMB-45 positivity in sentinel lymph nodes indicates micrometastasis and is associated with worse prognosis compared to HMB-45–negative lymph nodes. Therefore, patients with proven melanoma and nodal involvement represent a high-risk group where HMB-45 has prognostic relevance.
Clinical Applications
HMB-45 is widely used in the diagnosis of primary and metastatic melanoma. It assists in differentiating melanoma from non-melanocytic tumors and is commonly used as part of an immunohistochemical panel along with markers such as S-100, Melan-A, and SOX-10.
The marker is also useful in the detection of angiomyolipoma and perivascular epithelioid cell tumors (PEComas), where melanocytic differentiation is present. In surgical pathology, rapid HMB-45 staining has been applied to frozen sections during Mohs surgery to aid in melanoma treatment.
Methods of Detection and Interpretation
HMB-45 is detected using immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections. Proper tissue fixation and processing are essential for reliable staining.
In benign nevi, HMB-45 often shows nuclear staining in both thin and thick lesions, whereas in malignant lesions, the staining pattern is predominantly cytoplasmic. Basal keratinocytes in the epidermis serve as an internal positive control.
Strong, diffuse cytoplasmic staining in most tumor cells is interpreted as positive and supports a diagnosis of malignant melanoma or related melanocytic tumors. Patchy or weak staining is considered borderline and may be seen in dysplastic nevi or ambiguous melanocytic lesions, requiring correlation with other markers. Negative staining may be observed in intradermal nevi, non-melanocytic tumors, or melanomas with minimal pigmentation.
Prognostic Significance
In confirmed melanoma cases, HMB-45 positivity in sentinel lymph nodes indicating micrometastasis is associated with a poorer prognosis compared to metastasis-free nodes. Thus, Human Melanoma Black-45 contributes not only to diagnosis but also to prognostic assessment.
Limitations
Human Melanoma Black-45 can be detected in only 50–70% of melanomas, making it less sensitive than S-100 protein. It does not react well with intradermal nevi, normal adult melanocytes, spindle cell melanomas, or desmoplastic melanomas.
False-positive staining may occur in some non-melanocytic tumors. Because of these limitations, HMB-45 should never be used as a standalone marker and must always be interpreted in conjunction with morphology and other immunohistochemical markers.
